R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy

Go online to PeerView.com/NDY860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Find out if you are prepared to integrate cutting-edge
antibody and CAR-T options for the care of patients with multiple
myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum
activity, an expert panel will offer guidance on how pharmacists
can tackle the real-world challenges of MM management by
facilitating care with CD38 and BCMA-directed antibodies, as well
as CAR-T therapy, in a range of different treatment settings. Our
experts will provide insights into how pharmacists can help
modernize MM treatment protocols by ensuring appropriate care
coordination and addressing safety, dosing, and therapy delivery
considerations associated with CD38 and BCMA-directed treatment.
Participate in this CPE video activity to see if you are prepared
to lead the way to better outcomes for MM! Upon completion of this
activity, participants should be better able to: Describe the
mechanisms of action, dosing, efficacy evidence, and safety
evidence supporting the treatment roles of antibody-based and CAR-T
therapies in multiple myeloma (MM), including CD38 and
BCMA-directed agents; Implement pharmacist-guided strategies to
promote optimal clinical integration of established and emerging
antibody and cellular therapies across the spectrum of MM; and
Develop modernized patient-, staff-, and institution-directed
protocols to address practical aspects of care when using antibody
and cellular therapy platforms, including dosing, safety, patient
and staff counseling, and managing supportive therapies